Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Lentiviral Vector Market Be Worth By 2029?

The market size for lentiviral vectors has seen a swift surge over the past few years. From $14.37 billion in 2024, it is expected to inflate to $16.48 billion in 2025, noting a compound annual growth rate (CAGR) of 14.7%. This growth observed in the historic period is linked to the increased prevalence of genetic disorders, demand for gene delivery, the expansion of biotech and pharmaceutical companies, investment in clinical trials, and regulatory approvals.

There’s an anticipation of swift expansion in the lentiviral vector market in the forthcoming years. Its increase is projected to reach “$27.71 billion by 2029, with a compound annual growth rate (CAGR) of 13.9%. Factors contributing to this surge during the prediction period include the progression in personalized medicine, advancements in gene editing, increased demand for rare disease therapies, the popularity of lentiviral vector, provision for genomic medicine, and an emphasis on manufacturing scalability. Prevalent trends in the projected timeline encapsulate the extension of research and development, use in CAR-T cell therapy, emergence of next-gen vectors, utilization in vaccine formulations, and the enhancement of production methodologies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=14742&type=smp

Which Growth Drivers Are Shaping The Lentiviral Vector Market Outlook?

The lentiviral vectors market is anticipated to expand, driven by the rising incidence of chronic illnesses. Chronic diseases are long-lasting medical conditions that usually advance gradually and can persist for many years or even a lifetime. Factors such as aging populations, unhealthy living habits, urbanization, and environmental conditions are contributing to the rising incidence of these chronic diseases. Lentiviral vectors provide versatile and efficient solutions for creating vaccines and treatment approaches for such chronic diseases, meeting previously unmet medical needs and enhancing patient outcomes. For example, data from the British Heart Foundation, a cardiovascular research charity in the UK, revealed that in September 2024, around 7.6 million people in the UK were living with heart and circulatory diseases. These included approximately 4 million men and 3.6 million women. These diseases account for nearly 27% of all UK fatalities, resulting in over 170,000 deaths each year or about 480 deaths every day, equivalent to one death every three minutes. Consequently, the rising incidence of chronic diseases is fueling the lentiviral vectors market’s growth.

What Segmentation Insights Are Provided In The Lentiviral Vector Market Research?

The lentiviral vector market covered in this report is segmented –

1) By Product Type: Kits, Reagents And Consumables

2) By Indication: Cancer, Genetic Disorder, Infectious Disease, Veterinary Disease, Other Indications

3) By End User: Biotechnology Companies, Pharmaceutical Companies, Contract Research Organization (CRO), Academic And Research Institutes

Subsegments:

1) By Kits: Lentiviral Transduction Kits, Lentiviral Packaging Kits, Lentiviral Vector Production Kits

2) By Reagents and Consumables: Lentiviral Packaging Reagents, Lentiviral Vector Concentration Reagents, Transfection Reagents for Lentiviral Vectors

Which Notable Trends Are Transforming The Lentiviral Vector Market Outlook?

Major corporations in the lentiviral vectors market are concentrating on the creation of LV vector production platforms like LentiSure. The goal is to boost the effectiveness and reliability of lentivirus vector production used in cell-based immuno-oncology treatments. LentiSure, a LV vector production platform, has been designed to improve efficiency and solidity during the making of vectors. For instance, Yposkesi sk pharmteco, a manufacturer of viral vectors based in France, unveiled LentiSure in May 2023. It’s a sophisticated platform devised to upgrade lentiviral (LV) vector production, with an emphasis on enhancing the sturdiness and efficiency of lentivirus creation. This platform caters to the escalating need for durable and economically scalable viral-vector manufacturing techniques in cellular and gene therapies. It promises uniform product quality with average titers at cell culture harvest at approximately 10e7 IG/mL bioreactor volume, thus ensuring augmented productivity and success for cell therapy developers.

Which Companies Are Contributing Significantly To The Lentiviral Vector Market Growth?

Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/lentiviral-vector-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Lentiviral Vector Market?

North America was the largest region in the lentiviral vector market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=14742&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model